Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation.
about
Processing and transcriptome expansion at the mRNA 3' end in health and disease: finding the right endRegulated pre-mRNA splicing: the ghostwriter of the eukaryotic genomeAlternative cleavage and polyadenylation: the long and short of itAll's well that ends well: alternative polyadenylation and its implications for stem cell biologyRegulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in CancerAlternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR)Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?Alternative polyadenylation of mRNA precursors.Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth.Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.Ott1 (Rbm15) regulates thrombopoietin response in hematopoietic stem cells through alternative splicing of c-MplEpidermal growth-factor-induced transcript isoform variation drives mammary cell migration.A complex immunodeficiency is based on U1 snRNP-mediated poly(A) site suppression.Alternative polyadenylation: new insights from global analysesCleavage and polyadenylation specificity factor 1 (CPSF1) regulates alternative splicing of interleukin 7 receptor (IL7R) exon 6.Differentially expressed, variant U1 snRNAs regulate gene expression in human cellsAlternative polyadenylation can regulate post-translational membrane localization.Targeting RNA splicing for disease therapy.A U1 snRNP-specific assembly pathway reveals the SMN complex as a versatile hub for RNP exchangeAlterations in polyadenylation and its implications for endocrine disease.Premature polyadenylation of MAGI3 produces a dominantly-acting oncogene in human breast cancer.Splice-switching antisense oligonucleotides as therapeutic drugsU1 snRNP-Dependent Suppression of Polyadenylation: Physiological Role and Therapeutic Opportunities in Cancer.Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.Variant U1 snRNAs are implicated in human pluripotent stem cell maintenance and neuromuscular disease.Morphine regulates expression of μ-opioid receptor MOR-1A, an intron-retention carboxyl terminal splice variant of the μ-opioid receptor (OPRM1) gene via miR-103/miR-107.Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.Alternative polyadenylation of tumor suppressor genes in small intestinal neuroendocrine tumors.Intronic polyadenylation of PDGFRα in resident stem cells attenuates muscle fibrosis.Development of therapeutic splice-switching oligonucleotides.Insights into the U1 small nuclear ribonucleoprotein complex superfamily.Pharmacology of Modulators of Alternative Splicing.Regulation of soluble Flt-1 (VEGFR-1) production by hnRNP D and protein arginine methylation.Interorgan Communication Pathways in Physiology: Focus on Drosophila.Noncanonical registers and base pairs in human 5' splice-site selection.Mechanisms of immunomodulation by mammalian and viral decoy receptors: insights from structures.The role of RNA alternative splicing in regulating cancer metabolism.Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts.U1 snRNP-mediated poly(A) site suppression: beneficial and deleterious for mRNA fate
P2860
Q26746120-39D61354-BA53-4F60-B9B6-326A5AFB3177Q26861955-77C183D0-1767-4933-A771-17CBDA9FE878Q26864222-F9F86F28-B255-4795-B6AE-0DC81F9C702AQ26998409-CC7F6C8F-B434-4914-8B19-2181A218FB15Q27001635-7F48A955-C28E-470F-A782-09A168B48B1DQ28654409-70BA50F9-7372-4DCC-BEFC-9AFD6B981791Q31097489-4F51DA17-AB82-439A-97EF-5D7D800C2500Q33751398-1CFF6AEB-B440-480E-A9C9-D66097A12CA8Q33832891-6970D67A-6EA8-4240-ABEB-3631D83D2F97Q34774917-7B9771E5-A519-4965-A86F-EBD16767B139Q34911031-F2A00D30-4271-4EC9-B82F-B3CC48BBE681Q35056295-E4F3B9A5-4DB4-4AD9-A1B3-18B75FA39A99Q35063756-0283678E-6BD2-4169-BD88-CBFE8534D13CQ36328695-70A3613F-EF96-4B32-84EF-4D1445741F4EQ36418590-936FEF10-5B8F-49A0-B394-824F49C20677Q36481216-C203AD63-5C40-46B6-ABDD-E03E690B6038Q36580574-0A6689C6-6F77-47D7-9AB6-8465D7039E87Q36630940-E00CE9B5-5A0C-4942-BF50-87CDCFE1DFC7Q36780738-A6FD1234-92CA-4D21-AFEB-71FA603A28A5Q36806948-0ADFD275-655F-4FB2-8A6D-87EE7E8D35DEQ36824347-565F83DA-C8AE-4AB0-AEEC-7D8DBBA557BAQ36998997-82019AC0-7BE6-449F-848A-9D7BB5CA45EFQ37211004-3C6DDF2D-8375-4877-B276-E04BC90A3C34Q37304518-4F3EA521-5A8B-44A5-AF0F-0F9DD4FD6294Q37304724-526BA7ED-B47C-40E5-A291-CA80C4266251Q37507550-D1F8917A-035E-4BAF-BA92-322D7455E3CAQ37553516-6044418B-2C53-4670-B301-A9E34CC765F6Q37690917-0C8A2D36-A764-4C52-9A0F-E0F73B61F4F3Q37715730-374F6012-2581-4318-A960-D851D147BAE7Q37741521-BF1E891F-B328-472D-9EC7-C84358FBEFBCQ38211673-0A048AFB-BF1D-4CAC-A1C6-FB4F64B13614Q38255119-85C2239A-B6EF-497E-B496-F5A5F921C85DQ38776406-0583F868-A5A1-460A-9131-695413034438Q38806703-8B032366-16B1-4240-AE50-A09CA85ABBC6Q38812346-57DAF452-33D5-4ADF-82D7-09FFBB962B56Q38896235-19EE3B70-E826-434C-9F37-FDA53B63D14FQ39059671-0A86B2B8-8E7A-48CD-A3F6-278DA4CCBA98Q39253959-73C3C4C4-FFDD-42EC-9B7F-C7097564C206Q39439179-90A0E3C2-71C0-4A1E-A5A1-9F4F8F565A47Q41295325-6B34C84A-FF2B-426B-B864-6C941CB84B5A
P2860
Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Induction of antagonistic solu ...... by intronic polyA activation.
@en
Induction of antagonistic solu ...... by intronic polyA activation.
@nl
type
label
Induction of antagonistic solu ...... by intronic polyA activation.
@en
Induction of antagonistic solu ...... by intronic polyA activation.
@nl
prefLabel
Induction of antagonistic solu ...... by intronic polyA activation.
@en
Induction of antagonistic solu ...... by intronic polyA activation.
@nl
P2093
P2860
P1433
P1476
Induction of antagonistic solu ...... by intronic polyA activation.
@en
P2093
Clare V Lefave
Erik Henke
Francine M Jodelka
Gina Rocco
Luca Cartegni
Michelle L Hastings
Sandra Vorlová
P2860
P304
P356
10.1016/J.MOLCEL.2011.08.009
P577
2011-09-01T00:00:00Z